Muge Cevik

List of Publications by Year
in descending order

59 papers	4,354 citations	279701 23 h-index	155592 55 g-index
72 all docs	72 docs citations	72 times ranked	9364 citing authors

#	Article	IF	Citations
1	Indirect Protection by Reducing Transmission: Ending the Pandemic With Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination. Open Forum Infectious Diseases, 2022, 9, .	0.4	38
2	Acute hepatitis of unknown origin in children. BMJ, The, 2022, 377, o1197.	3.0	22
3	Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: Update of a living systematic review and meta-analysis. PLoS Medicine, 2022, 19, e1003987.	3.9	44
4	A population framework for predicting the proportion of people infected by the far-field airborne transmission of SARS-CoV-2 indoors. Building and Environment, 2022, , 109309.	3.0	5
5	Association between women's authorship and women's editorship in infectious diseases journals: a cross-sectional study. Lancet Infectious Diseases, The, 2022, 22, 1455-1464.	4.6	14
6	Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational Study. Clinical Infectious Diseases, 2021, 73, e2095-e2106.	2.9	218
7	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission Dynamics Should Inform Policy. Clinical Infectious Diseases, 2021, 73, S170-S176.	2.9	102
8	SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe, The, 2021, 2, e13-e22.	3.4	1,111
9	Towards an accurate and systematic characterisation of persistently asymptomatic infection with SARS-CoV-2. Lancet Infectious Diseases, The, 2021, 21, e163-e169.	4.6	137
10	On the Effect of Age on the Transmission of SARS-CoV-2 in Households, Schools, and the Community. Journal of Infectious Diseases, 2021, 223, 362-369.	1.9	257
11	Support for self-isolation is critical in covid-19 response. BMJ, The, 2021, 372, n224.	3.0	37
12	Prevalence of Asymptomatic SARS-CoV-2 Infection. Annals of Internal Medicine, 2021, 174, 283-284.	2.0	5
13	How to detect and reduce potential sources of biases in studies of SARS-CoV-2 and COVID-19. European Journal of Epidemiology, 2021, 36, 179-196.	2.5	93
14	What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? A harmonised, global longitudinal observational study protocol. BMJ Open, 2021, 11, e043887.	0.8	51
15	Public health actions to control new SARS-CoV-2 variants. Cell, 2021, 184, 1127-1132.	13.5	149
16	The role of asymptomatic and pre-symptomatic infection in SARS-CoV-2 transmissionâ€”a living systematic review. Clinical Microbiology and Infection, 2021, 27, 511-519.	2.8	109
17	Should masks be worn outdoors?. BMJ, The, 2021, 373, n1036.	3.0	8
18	Expect the unexpected â€“ Implications for next phase of COVID-19 response. Infection Prevention in Practice, 2021, 3, 100118.	0.6	0

#	Article	IF	Citations
19	SARS-CoV-2 variants and considerations of inferring causality on disease severity. Lancet Infectious Diseases, The, 2021, 21, 1472-1474.	4.6	25
20	Networks of SARS-CoV-2 transmission. Science, 2021, 373, 162-163.	6.0	37
21	Gender disparities in coronavirus disease 2019 clinical trial leadership. Clinical Microbiology and Infection, 2021, 27, 1007-1010.	2.8	22
22	Aims and challenges of building national traineeÂnetworks in clinical microbiology and infectious disease disciplines. Future Microbiology, 2021, 16, 687-695.	1.0	6
23	COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants. Cell, 2021, 184, 5077-5081.	13.5	114
24	Covid-19 vaccination: evidence of waning immunity is overstated. BMJ, The, 2021, 374, n2320.	3.0	30
25	Covid-19 vaccines, immunity, and boosters. BMJ, The, 2021, 375, n3105.	3.0	16
26	Challenges of Interpreting Cytomegalovirus DNAemia and Its Potential Association With Chronic Lung Disease in Children and Adolescents With Perinatally Acquired Human Immunodeficiency Virus Infection. Clinical Infectious Diseases, 2020, 70, 989-990.	2.9	2
27	Non-typeable Haemophilus influenzae-associated early pregnancy loss: an emerging neonatal and maternal pathogen. Infection, 2020, 48, 285-288.	2.3	8
28	Pulmonary Illness Related to E-Cigarette Use. New England Journal of Medicine, 2020, 382, 384-386.	13.9	15
29	Global status of Toxoplasma gondii infection and associated risk factors in people living with HIV. Aids, 2020, 34, 469-474.	1.0	33
30	Emergent Resistance to Dolutegravir Among INSTI-NaÃ¯ve Patients on First-line or Second-line Antiretroviral Therapy: A Review of Published Cases. Open Forum Infectious Diseases, 2020, 7, ofaa202.	0.4	25
31	Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ, The, 2020, 371, m3862.	3.0	515
32	Hospital-Acquired SARS-CoV-2 Infection. JAMA - Journal of the American Medical Association, 2020, 324, 2155.	3.8	123
33	Reopening Primary Schools during the Pandemic. New England Journal of Medicine, 2020, 383, 981-985.	13.9	142
34	Investigation of a healthcareâ€associated Candida tropicalis candidiasis cluster in a haematology unit and a systematic review of nosocomial outbreaks. Mycoses, 2020, 63, 326-333.	1.8	17
35	Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3. Lancet, The, 2020, 396, 693-724.	6.3	87
36	COVID-19 pandemicâ€”a focused review for clinicians. Clinical Microbiology and Infection, 2020, 26, 842-847.	2.8	289

#	Article	IF	Citations
37	A Subgroup of Patients With Hospital-acquired Pneumonia Do Not Require Broad-spectrum Gram-negative Antimicrobial Coverage. Clinical Infectious Diseases, 2020, 71, e710-e713.	2.9	0
38	An exceptional case report of disseminated cryptococcosis in a hitherto immunocompetent patient. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2020, 62, e3.	0.5	4
39	Risk factors associated with poor clinical outcome in pyogenic spinal infections: 5-yearsâ€™ intensive care experience. Journal of Infection in Developing Countries, 2020, 14, 36-41.	0.5	2
40	How scientists and physicians use Twitter during a medical congress. Clinical Microbiology and Infection, 2019, 25, 1561.e7-1561.e12.	2.8	18
41	Organization and training at national level of antimicrobial stewardship and infection control activities in Europe: an ESCMID cross-sectional survey. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 2061-2068.	1.3	15
42	Social media to engage, communicate and interact. Clinical Microbiology and Infection, 2019, 25, 1165-1166.	2.8	2
43	Transfusion-Transmitted Malaria: A Systematic Review and Meta-analysis. Open Forum Infectious Diseases, 2019, 6, ofz283.	0.4	21
44	The Convergent Effect of International Collaboration between Young Leaders of Two Global Societies: Strengthening Microbiology Education and Training Practices Worldwide. Journal of Microbiology and Biology Education, 2019, 20, 50.	0.5	2
45	A pilot experience of common European infectious diseases curriculum for medical students: the IDEAL summer school. Future Microbiology, 2019, 14, 369-372.	1.0	1
46	Current mentorship practices in the training of the next generation of clinical microbiology and infectious disease specialists: an international cross-sectional survey. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 659-665.	1.3	10
47	Comment on: Doxycycline in UK guidelines for hospital-acquired pneumonia: where is the evidence base?. Journal of Antimicrobial Chemotherapy, 2019, 74, 1765-1766.	1.3	2
48	Insights into HIV-1 capsid inhibitors in preclinical and early clinical development as antiretroviral agents. Expert Opinion on Investigational Drugs, 2019, 28, 1021-1024.	1.9	3
49	Management of Orbital Complications of Acute Rhinosinusitis in Pediatric Patients. Pediatric Infectious Disease Journal, 2019, 38, 994-998.	1.1	12
50	Fixed dose darunavir boosted with cobicistat combined with emtricitabine and tenofovir alafenamide fumarate. Current Opinion in HIV and AIDS, 2018, 13, 315-319.	1.5	4
51	Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet, The, 2018, 391, 668-678.	6.3	140
52	Dolutegravir use in combination with rifampicin-based tuberculosis therapy: 3 years of real-world experience in a large UK teaching hospital. Sexually Transmitted Infections, 2018, 94, 420-420.	0.8	5
53	Experience of managing TB/HIV infection in a regional UK center over a 5 year period. , 2016, , .		0
54	A switch to Raltegravir improves antiretroviral associated hepatotoxicity in individuals co-infected with HIV and hepatitis C. Journal of Infection, 2014, 69, 190-193.	1.7	7

#	Article	IF	Citations
55	Genetic Determinants of Idiopathic Noncirrhotic Portal Hypertension in HIV-Infected Patients. Clinical Infectious Diseases, 2013, 56, 1117-1122.	2.9	27
56	Raltegravir switch improves hepatitis C transaminitis in HIV-1 and hepatitis C (HCV) co-infected individuals. Retrovirology, 2012, 9, .	0.9	1
57	Seroprevalence of IgG antibodies against Bordetella pertussis in healthy individuals aged 4â€“24 years in Turkey. Clinical Microbiology and Infection, 2008, 14, 388-390.	2.8	10
58	Towards an Accurate and Systematic Characterization of Persistently Asymptomatic Infection with SARS-CoV-2. SSRN Electronic Journal, 0, , .	0.4	6
59	SARS-CoV-2, SARS-CoV-1 and MERS-CoV Viral Load Dynamics, Duration of Viral Shedding and Infectiousness: A Living Systematic Review and Meta-Analysis. SSRN Electronic Journal, 0, , .	0.4	40